364: Closing a zombie biotech, and Lilly's disappointing obesity readout
The Readout Loud
00:00
Eli Lilly's Obesity Drug Setback
This chapter discusses the disappointing phase three results of Eli Lilly's obesity drug Orforglipron, which fell short of expectations despite initial promising data. It explores the implications for the biotech industry, including manufacturing challenges and side effects, while comparing small molecule GLP-1 options to existing injectable treatments.
Transcript
Play full episode
